Peer-reviewed veterinary case report
Anti-Leishmania antibody levels and inflammation proteins in dogs
By Cantos-Barreda, Ana et al.·Published in Veterinary parasitology·2018·University of Murcia, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Relationship between serum anti-Leishmania antibody levels and acute phase proteins in dogs with canine leishmaniosis.
- Species:
- dog
Plain-English summary
A group of dogs with leishmaniosis, a disease caused by a parasite, had their blood tested for antibodies and certain proteins to see how they were affected by the illness. The study found that dogs with higher levels of antibodies showed more health issues. While the tests used to measure the antibodies were helpful, they were more effective for diagnosing the disease than for monitoring treatment. Understanding these relationships can help veterinarians better manage and treat dogs suffering from leishmaniosis.
People also search for: dog leishmaniosis symptoms · dog blood test for leishmaniosis · treatment for leishmaniosis in dogs
Abstract
This study examined the relationship between two serologic assays which quantify anti-Leishmania antibodies (a commercial enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay (TR-IFMA)) and selected acute phase proteins (APPs) and analytes related to protein concentration. Data were obtained from 205 canine serum samples from different veterinary clinics located in an area in which canine leishmaniosis (CanL) is endemic. The samples were submitted to the Interdisciplinary Laboratory of Clinical Analysis (Interlab-UMU), University of Murcia, Spain, for analysis. The biochemical analytes evaluated were serum ferritin, C-reactive protein (CRP), haptoglobin, paraoxonase-1 (PON-1) and albumin as APPs and total proteins and globulins as indicative analytes of protein concentration. Samples were submitted for the initial diagnosis of CanL, or to monitor the response to treatment in patients with CanL. The evaluation of the biochemical analytes did not show differences between Leishmania-seronegative and Leishmania-seropositive dogs. However, dogs with high antibody titers showed more pronounced clinicopathological abnormalities. Both serological assays had correlations of different significance with the biochemical analytes, showing higher significant correlations with total proteins and globulins than with the rest of the analytes. When the samples submitted for diagnosis and treatment monitoring were analyzed separately, serological assays showed lower correlation in samples for treatment monitoring (r = 0.531, p <  0.0001) than in samples for diagnosis (r = 0.769, p <  0.0001). In addition, higher correlations were found between TR-IFMA and analytes such as serum ferritin and CRP in the treatment monitoring group than with the ELISA. These results may help to clarify the relationship between anti-Leishmania antibody levels and selected biochemical analytes related to inflammation and protein concentration in CanL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30197018/